all report title image
  • Published On : Dec 2021
  • Code : CMI4799
  • Industry : Biotechnology
  • Pages : 168
  • Formats :

T-cell lymphoma is a type of blood cancer which arises from unregulated growth and multiplication of T-cell lymphocytes present in the immune system of the human body. T-cell lymphoma is of two major types: peripheral T-cell lymphoma and T-cell lymphoblastic lymphoma. Peripheral T-cell lymphoma can be of various types such as cutaneous T-cell lymphoma, intestinal T-cell lymphoma, Angio-immuno-blastic T-cell lymphoma, anaplastic large cell lymphoma, follicular T-cell lymphoma, and others. The cause of T-cell lymphomas is unknown in most cases, however some of the risk factors associated with occurrence of T-cell lymphoma include viral infections such as Epstein-Barr virus or medical conditions such as coeliac disease. T-cell lymphoma can be diagnosed with the help of a tissue biopsy, blood cell counts, PET (positron emission tomography) scan, CT (computed tomography) scan, MRI (magnetic resonance imaging) scan, and others. There are various treatments available for T-cell lymphoma such as chemotherapy, radiotherapy, immunotherapy, anti-viral therapy, stem cell transplantation, and others.

The global T-cell lymphoma market is estimated to be valued at US$ 1,627.1 million in 2021 and is expected to exhibit a CAGR of 9.8% over the forecast period (2021-2028).

Figure 1. Global T-cell Lymphoma Market Share (%), By Region, 2021

T-Cell Lymphoma  | Coherent Market Insights

The increasing incidence of T-cell lymphoma is expected to drive the growth of the global T-cell Lymphoma market over the forecast period.

For instance, according to an article published by the Cancer Causes Control: CCC journal in May 2019, it is estimated that non-Hodgkin lymphoma (NHL) ranks amongst the top 10 most common types of cancer with around 510,000 new cases reported globally in 2018. The same source also implies that a slight increase in incidence of NHL would be observed in the near future in several areas of the globe such as Asia, Latin America, and others. T-cell lymphoma is a type of NHL, thus growing incidence of NHL is expected to have a positive impact on global T-cell lymphoma market.

CMI table icon

T-cell Lymphoma Market Report Coverage

Report Coverage Details
Base Year: 2020 Market Size in 2021: US$ 1,627.1 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2021 to 2028
Forecast Period 2021 to 2028 CAGR: 9.8% 2028 Value Projection: US$ 2,495.4 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Lymphoma Type: Peripheral T-cell Lymphoma (Cutaneous T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angio-immuno-blastic T-cell Lymphoma, Others (Intestinal T-cell Lymphoma, Follicular T-cell lymphoma, etc.)), T-cell Lymphoblastic Lymphoma
  • By Therapy: Radiotherapy, Chemotherapy, Immunotherapy, Stem Cell Transplantation, Others (Antiviral Therapy, etc.)
Companies covered:

F. Hoffmann-La Roche Ltd, Biocryst Pharmaceuticals Inc., Bristol-Myers Squibb Company, Kyowa Kirin Co., Ltd., Genmab A/S, Seagen Inc., GlaxoSmithKline plc., Johnson and Johnson Private Limited, Elorac, Acrotech Biopharma, Merck and Co. Inc., Novartis AG, SHIONOGI & Co., Ltd., Spectrum Pharmaceuticals Inc., and Bausch Health Companies Inc.

Growth Drivers:
  • Increasing research in the field of T-cell lymphoma therapeutics
  • Increasing products approvals and launches
Restraints & Challenges:
  • Side effects ( fatigue, hair loss, anemia, etc.) of chemotherapy drugs 

Figure 2. Global T-cell Lymphoma Market Value (US$ Mn), By Therapy Type, 2021

T-Cell Lymphoma  | Coherent Market Insights

The increasing research and development activities for the development of novel therapeutics for the treatment of T-cell lymphoma is expected to drive the market growth over the forecast period.

Market players are focused on thorough research in the field of T-cell lymphoma in order to develop newer and improved therapies for the treatment of T-cell lymphoma. Manufacturers in the global T-cell lymphoma market are engaged in obtaining regulatory approvals for their T-cell lymphoma treatment therapies.

For instance, in May 2020, Takeda Pharmaceutical Company Limited, a Japan based pharmaceutical company, received approval from China’s National Medical Products Administration (NMPA) for its injection ADCETRIS (brentuximab vedotin) indicated for treatment of patients with relapsed or refractory systemic Anaplastic Large Cell Lymphoma (a type of T-cell lymphoma).

Global T-cell Lymphoma Market – Impact of Coronavirus (COVID-19) Pandemic

Coronavirus (COVID-19) outbreak was first reported on December 31, 2019, in Wuhan, China. The World Health Organization declared COVID-19, as pandemic on March 11, 2020. According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 256,480,022 cases and 5,145,002 deaths due to coronavirus (COVID-19) were reported till November 21, 2021, across the globe.

The COVID-19 pandemic and lockdown in various countries across the globe has negatively impacted the financial status of businesses across all sectors. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry mainly due to strict lockdown in several regions. Likewise, COVID-19 pandemic is expected to have a negative impact on global T-cell lymphoma market over the forecast period, owing to disruption in cancer treatment services and halt of clinical trials related to treatment of cancer. For instance, according to a report published by the World Health Organization in July 2020, around 42% of the countries around the world have disrupted services for cancer treatment in lieu of COVID-19 pandemic.

Global T-cell Lymphoma Market Restraint

The side effects of chemotherapy drugs used in the treatment of T-cell lymphoma are the factors that are expected to hinder growth of the global T-cell lymphoma market over the forecast period. For instance, according to data provided by the American Cancer Society as of May 2020, chemotherapy drugs are generally associated with side effects such as fatigue, hair loss, anemia (low red blood cell counts), nausea and vomiting, appetite changes, constipation, diarrhea, and others.

Key Players

Major players operating in the global T-cell lymphoma market include F. Hoffmann-La Roche Ltd, Biocryst Pharmaceuticals Inc., Bristol-Myers Squibb Company, Kyowa Kirin Co., Ltd., Genmab A/S, Seagen Inc., GlaxoSmithKline plc., Johnson and Johnson Private Limited, Elorac, Acrotech Biopharma, Merck and Co. Inc., Novartis AG, SHIONOGI & Co., Ltd., Spectrum Pharmaceuticals Inc., and Bausch Health Companies Inc.

Lymphoma is the most common type of blood cancer which occurs when white blood cells called lymphocytes grow and multiply uncontrollably in the human body. Lymphocytes are a part of the immune system of the body, which travel around the body through the lymphatic system and help fight microbial infection. Lymphocytes are of two types B lymphocytes (B-cells) and T lymphocytes (T-cells). Lymphomas that develop from T lymphocytes are known as non-Hodgkin lymphomas. T-cell lymphoma can affect body parts including spleen, lymph node, bone marrow, blood, and others. T-cell lymphoma can be majorly categorized into two types i.e. peripheral T-cell lymphoma and T-cell lymphoblastic lymphoma. The symptoms associated with T-cell lymphoma depend upon the type of T-cell lymphoma. One of the most common symptom of t-cell lymphoma includes swollen lymph node or nodes. Other symptoms include swollen liver or spleen, skin rash, abnormal blood cell count, and others.

Market Dynamics

The increasing incidence of T-cell lymphoma, rising research and development activities for the development of novel therapeutics for the treatment of T-cell lymphoma are the major factors that are expected to drive growth of the global T-cell lymphoma market over the forecast period. Moreover, increasing adoption of inorganic growth strategies such as acquisitions and collaborations by key players operating in the market are expected to boost the global T-cell lymphoma market.

For instance, according to a review article published in the CA: A Cancer Journal for Clinicians in December 2019, it has been estimated that there are around 80,000 people suffering from non-Hodgkin lymphomas (NHL) per year in U.S. and this is expected to increase in the near future.

Key features of the study:

  • This report provides in-depth analysis of the global T-cell lymphoma market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global T-cell lymphoma market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include F. Hoffmann-La Roche Ltd, Biocryst Pharmaceuticals Inc., Bristol-Myers Squibb Company, Kyowa Kirin Co., Ltd., Genmab A/S, Seagen Inc., GlaxoSmithKline plc., Johnson and Johnson Private Limited, Elorac, Acrotech Biopharma, Merck and Co. Inc., Novartis AG, SHIONOGI & Co., Ltd., Spectrum Pharmaceuticals Inc., and Bausch Health Companies Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global T-cell lymphoma market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global T-cell lymphoma market

Detailed Segmentation:

  • Global T-cell Lymphoma Market, By Lymphoma Type:
    • Peripheral T-cell Lymphoma
      • Cutaneous T-cell Lymphoma
      • Anaplastic Large Cell Lymphoma
      • Angio-immuno-blastic T-cell Lymphoma
      • Others (Intestinal T-cell Lymphoma, Follicular T-cell lymphoma, etc.)
    • T-cell Lymphoblastic Lymphoma
  • Global T-cell Lymphoma Market, By Therapy :
    • Radiotherapy
    • Chemotherapy
    • Immunotherapy
    • Stem Cell Transplantation
    • Others (Antiviral Therapy, etc.)
  • Global T-cell Lymphoma Market, By Region:
    • North America
      • By Lymphoma Type
        • Peripheral T-cell Lymphoma
          • Cutaneous T-cell Lymphoma
          • Anaplastic Large Cell Lymphoma
          • Angio-immuno-blastic T-cell Lymphoma
          • Others (Intestinal T-cell Lymphoma, Follicular T-cell lymphoma, etc.)
        • T-cell Lymphoblastic Lymphoma
      • By Therapy
        • Radiotherapy
        • Chemotherapy
        • Immunotherapy
        • Stem Cell Transplantation
        • Others (Antiviral Therapy, etc.)
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Lymphoma Type
        • Peripheral T-cell Lymphoma
          • Cutaneous T-cell Lymphoma
          • Anaplastic Large Cell Lymphoma
          • Angio-immuno-blastic T-cell Lymphoma
          • Others (Intestinal T-cell Lymphoma, Follicular T-cell lymphoma, etc.)
        • T-cell Lymphoblastic Lymphoma
      • By Therapy
        • Radiotherapy
        • Chemotherapy
        • Immunotherapy
        • Stem Cell Transplantation
        • Others (Antiviral Therapy, etc.)
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Lymphoma Type
        • Peripheral T-cell Lymphoma
          • Cutaneous T-cell Lymphoma
          • Anaplastic Large Cell Lymphoma
          • Angio-immuno-blastic T-cell Lymphoma
          • Others (Intestinal T-cell Lymphoma, Follicular T-cell lymphoma, etc.)
        • T-cell Lymphoblastic Lymphoma
      • By Therapy
        • Radiotherapy
        • Chemotherapy
        • Immunotherapy
        • Stem Cell Transplantation
        • Others (Antiviral Therapy, etc.)
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Lymphoma Type
        • Peripheral T-cell Lymphoma
          • Cutaneous T-cell Lymphoma
          • Anaplastic Large Cell Lymphoma
          • Angio-immuno-blastic T-cell Lymphoma
          • Others (Intestinal T-cell Lymphoma, Follicular T-cell lymphoma, etc.)
        • T-cell Lymphoblastic Lymphoma
      • By Therapy
        • Radiotherapy
        • Chemotherapy
        • Immunotherapy
        • Stem Cell Transplantation
        • Others (Antiviral Therapy, etc.)
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Lymphoma Type
        • Peripheral T-cell Lymphoma
          • Cutaneous T-cell Lymphoma
          • Anaplastic Large Cell Lymphoma
          • Angio-immuno-blastic T-cell Lymphoma
          • Others (Intestinal T-cell Lymphoma, Follicular T-cell lymphoma, etc.)
        • T-cell Lymphoblastic Lymphoma
      • By Therapy
        • Radiotherapy
        • Chemotherapy
        • Immunotherapy
        • Stem Cell Transplantation
        • Others (Antiviral Therapy, etc.)
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Lymphoma Type
        • Peripheral T-cell Lymphoma
          • Cutaneous T-cell Lymphoma
          • Anaplastic Large Cell Lymphoma
          • Angio-immuno-blastic T-cell Lymphoma
          • Others (Intestinal T-cell Lymphoma, Follicular T-cell lymphoma, etc.)
        • T-cell Lymphoblastic Lymphoma
      • By Therapy
        • Radiotherapy
        • Chemotherapy
        • Immunotherapy
        • Stem Cell Transplantation
        • Others (Antiviral Therapy, etc.)
      • By Country/Region
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • F. Hoffmann-La Roche Ltd*
      • Company Overview
      • Material Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • Biocryst Pharmaceuticals Inc.
    • Bristol-Myers Squibb Company
    • Kyowa Kirin Co., Ltd.
    • Genmab A/S
    • Seagen Inc.
    • GlaxoSmithKline plc.
    • Johnson and Johnson Private Limited
    • Elorac
    • Acrotech Biopharma         
    • Merck and Co. Inc.
    • Novartis AG
    • SHIONOGI & Co., Ltd.
    • Spectrum Pharmaceuticals Inc.
    • Bausch Health Companies Inc.

“*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

The global T-cell lymphoma market size is estimated to be valued at US$ 1,627.1 million in 2021 and is expected to exhibit a CAGR of 9.8% between 2021 and 2028.
Increasing research and development activities for the development of novel therapeutics and increasing product launches and regulatory approvals for the treatment of T-cell lymphoma are expected to drive the market growth over the forecast period.
Chemotherapy segment is expected to hold the major market share, owing to increasing product approvals and launches during the forecast period.
North America holds the largest market share in the market.
Major factors hampering growth of the market include the side effects of chemotherapy drugs used in the treatment of T-cell lymphoma.
Major players operating in the market include F. Hoffmann-La Roche Ltd, Biocryst Pharmaceuticals Inc., Bristol-Myers Squibb Company, Kyowa Kirin Co., Ltd., Genmab A/S, Seagen Inc., GlaxoSmithKline plc., Johnson and Johnson Private Limited, Elorac, Acrotech Biopharma, Merck and Co. Inc., Novartis AG, SHIONOGI & Co., Ltd., Spectrum Pharmaceuticals Inc., and Bausch Health Companies Inc.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo